Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128650) titled 'Observational Study on the Efficacy and Safety of Tocilizumab in the Real-World Treatment of Refractory Interstitial Pneumonia Associated with Anti-Synthetase Syndrome' on July 23.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: China-Japan Friendship Hospital
Condition:
Antisynthetase syndrome-associated interstitial lung disease
Intervention:
Tocilizumab group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-07-30
Target Sample Size: Tocilizumab group:39;Conventional treatment group:78;
Countries of Recruitment:
China
To know more, vis...